Fecal Microbiota Transplantation to Patients with Refractory Very Early Onset Ulcerative Colitis

Yodoshi, Toshifumi; Hurt, Thomas L.

doi:10.5223/pghn.2018.21.4.355

Cited by 7 publications

(7 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FMT involves the transferring of a fecal matter solution from a donor's to a recipient's intestine to alter the gut microbiota and grant a clinical benefit [ 31 ]. In a case report by Yodoshi and Hurt, a five-year-old female was treated using FMT for her diagnosed UC that had affected the entire colon at the age of two years and 10 months [ 11 ]. The patient achieved clinical remission after one week, with a pediatric ulcerative colitis activity index (PUCAI) score of 0.…”

Section: Discussionmentioning

confidence: 99%

“…After three months, the fecal analysis demonstrated that the patient's intestinal flora was similar to the donor's fecal matter. As a result, clinical remission of UC activity was sustained for a period of two years since the study was published [ 11 ]. An adequate understanding of the mechanisms of VEO-IBD and disease advancement is needed to devise targeted therapeutic strategies for this patient population and improve their outcomes [ 17 ].…”

Section: Discussionmentioning

confidence: 99%

“…A meta-analysis by Ungaro et al showed that antibiotic use is strongly associated with IBD and that early use in life increases the risk of developing the condition [ 9 ]. Furthermore, it is widely recognized that antibiotics can alter the gut microbiota and promote dysbiosis, which has partly driven therapeutic options like fecal microbiota transplantation (FMT) [ 8 , 10 , 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Development of Very-Early-Onset Inflammatory Bowel Disease After Multiple Early-Life Antibiotic Exposures: A Case Report and Literature Review

Miró-González¹,

Maldonado-Chaar²,

Zambrana-Valenzuela³

et al. 2023

Cureus

View full text Add to dashboard Cite

The use of antibiotics has increased drastically over the last few decades. Many antibiotics can target the commensal microbiota and promote gut dysbiosis. These alterations contribute to disease onset and exacerbation. Although the etiology of inflammatory bowel disease (IBD) is mostly unknown, it involves a complex interaction among host genetics, microbiota, environmental factors, and aberrant immune responses. Studies have shown a relationship between very-early-onset inflammatory bowel disease (VEO-IBD) and microbiota alterations. The case discussed in this report endorses the current clinical evidence for this interaction. This is an anonymous record review with no identifiers involving a 23-month-old female patient who was brought to the emergency department by her parents due to persistent bloody diarrhea. Eight days before the presentation, she had experienced watery diarrhea that progressed to bloody stools. The patient had a history of acute otitis media, acute enteritis, and right-arm cutaneous abscess, for which she had received multiple antibiotic therapies. Strategies to manipulate the microbiome through diet, probiotics, antibiotics, or fecal microbiota transplantation (FMT) may be used therapeutically to modulate disease activity. A high index of clinical suspicion for VEO-IBD should be maintained for patients with a history of multiple, recurrent antibiotic use. We believe this case report will raise awareness about the issue of early anaerobic antibiotic exposure and help prevent its unnecessary use and, consequently, prevent gut microbiota dysbiosis that can lead to VEO-IBD. Also, our literature review will hopefully prompt clinicians to consider alternative therapeutic options for this patient population, such as rebuilding intestinal microbiota composition to improve VEO-IBD activity.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Development of Very-Early-Onset Inflammatory Bowel Disease After Multiple Early-Life Antibiotic Exposures: A Case Report and Literature Review

Miró-González¹,

Maldonado-Chaar²,

Zambrana-Valenzuela³

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…et al, 2016). To the best of our knowledge, the youngest reported patient that underwent FMT for very early-onset IBD was 2 years and 3 months old (Yodoshi and Hurt, 2018).…”

Section: Conveying the Present To The Future For Fighting Against Antmentioning

confidence: 99%

Gut Microbiota Modulation for Multidrug-Resistant Organism Decolonization: Present and Future Perspectives

et al. 2019

View full text Add to dashboard Cite

The emergence of antimicrobial resistance (AMR) is of great concern to global public health. Treatment of multi-drug resistant (MDR) infections is a major clinical challenge: the increase in antibiotic resistance leads to a greater risk of therapeutic failure, relapses, longer hospitalizations, and worse clinical outcomes. Currently, there are no validated treatments for many MDR or pandrug-resistant (PDR) infections, and preventing the spread of these pathogens through hospital infection control procedures and antimicrobial stewardship programs is often the only tool available to healthcare providers. Therefore, new solutions to control the colonization of MDR pathogens are urgently needed. In this narrative review, we discuss current knowledge of microbiota-mediated mechanisms of AMR and strategies for MDR colonization control. We focus particularly on fecal microbiota transplantation for MDR intestinal decolonization and report updated literature on its current clinical use.

show abstract

“…A valid alternative to cyclosporine or infliximab as rescue therapy in patients with acute severe UC is still lacking 77–79. Antibodies toward interleukins (ILs)-12/23 (ustekinumab) and tofacitinib (a not biologic small molecule inhibiting Janus Kinase) have been used in small series of patients with severe UC but it is too early to hypothesize their use 80,81…”

Section: Future Directionsmentioning

confidence: 99%

<p>Has infliximab influenced the course and prognosis of acute severe ulcerative colitis?</p>

Papi¹,

Latella²,

Frieri³

2019

BTT

View full text Add to dashboard Cite

Ulcerative colitis (UC) still has no definitive cure since its etiology remains unclear. In recent years, considerable progress has been made with regard to our knowledge of the pathogenesis of UC. Advances in biotechnology have led to the development of biologic therapies which selectively target single key mediators or receptors involved in the pathogenesis of the disease – ie, tumor necrosis factor (TNF)-α, integrin, interleukins 12/23. Biologic therapies caused a revolution in the treatment of UC, providing specific options for patients refractory to conventional treatment. In recent years, antibodies anti-TNFα and anti-integrin have shown efficacy in improving the course and prognosis of ambulatory patients with moderate-to-severe UC. Nevertheless, whether biologics have brought so many benefits also for hospitalized patients with acute severe UC is still debated. Acute severe UC is a potentially life-threatening condition that affects up to 25% of patients during the course of their disease. It requires hospital admission due to the risk of complications and death, and it can necessitate urgent colectomy. Major adverse outcomes of acute severe UC are mortality and colectomy. The aim of this systematic review of the literature was to analyze the impact of biologics, in particular infliximab, on the course and prognosis of acute severe UC. Mortality and colectomy rates were considered as outcome measures.

show abstract

Fecal Microbiota Transplantation to Patients with Refractory Very Early Onset Ulcerative Colitis

Cited by 7 publications

References 13 publications

Development of Very-Early-Onset Inflammatory Bowel Disease After Multiple Early-Life Antibiotic Exposures: A Case Report and Literature Review

Development of Very-Early-Onset Inflammatory Bowel Disease After Multiple Early-Life Antibiotic Exposures: A Case Report and Literature Review

Gut Microbiota Modulation for Multidrug-Resistant Organism Decolonization: Present and Future Perspectives

<p>Has infliximab influenced the course and prognosis of acute severe ulcerative colitis?</p>

Contact Info

Product

Resources

About